Special Issue "The Microbiome/Virome Interface during COVID-19"

A special issue of Microorganisms (ISSN 2076-2607).

Deadline for manuscript submissions: closed (30 November 2020).

Special Issue Editor

Dr. Antonio Riva
E-Mail Website
Guest Editor
1. Faculty of Life Sciences and Medicine, King's College London, London SE1 1UL, UK
2. Foundation for Liver Research, Institute of Hepatology, London SE5 9NT, UK
Interests: cellular and molecular immunology; inflammation; innate immunity; adaptive immunity; immunology of infectious diseases; liver immunology; viral immunology; peptides and vaccines; biomarkers of disease; multiparametric flow cytometry; luminex and other multiplex assessments; statistics; bioinformatics
Special Issues and Collections in MDPI journals

Special Issue Information

Dear Colleagues,

The SARS-CoV-2 pandemic is causing global disruption and has burdened health systems worldwide. SARS-CoV-2 has a relatively broad tropism, due to the widespread expression of its cellular receptor ACE2; this includes the gastrointestinal (GI) system, and COVID-19 patients with COVID-related GI complications tend to develop more severe disease outcomes. Disruption of the gut barrier, intestinal dysbiosis, and associated immune alterations have been described as pathogenetic mechanisms in a plethora of health conditions, but it is still unclear how SARS-CoV-2/COVID-19 affects the intestinal environment, the gut microbiome, and the progression of other viral infections in co-infected patients or vice versa. The aim of this Special Issue of The Microbiome/Virome Interface during COVID-19 is to collect recent evidence from basic and translational research to answer these questions.

We welcome submissions of original research papers, brief research reports, mini-reviews, and full reviews detailing evidence at a cellular, molecular, and/or immunological level. This includes, but is not limited to, the following two-way relationships:

  • SARS-CoV-2/COVID-19 and intestinal cells;
  • SARS-CoV-2/COVID-19 and bacterial or fungal intestinal dysbiosis;
  • SARS-CoV-2/COVID-19 and intestinal phage signatures;
  • SARS-CoV-2/COVID-19 and the gut–liver/lung/brain axes;
  • SARS-CoV-2/COVID-19 and gut/immune interactions;
  • SARS-CoV-2/COVID-19 and HBV/HCV/HIV infections.

Dr. Antonio Riva
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Microorganisms is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • SARS-CoV-2/COVID-19
  • microbiome
  • dysbiosis
  • gut
  • co-infection
  • immunity
  • commensal flora
  • opportunistic infection
  • virus
  • phage
  • bacterial
  • fungal
  • innate immunity
  • inflammation

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Review

Review
Is Gut Microbiota Dysbiosis a Predictor of Increased Susceptibility to Poor Outcome of COVID-19 Patients? An Update
Microorganisms 2021, 9(1), 53; https://doi.org/10.3390/microorganisms9010053 - 28 Dec 2020
Cited by 4 | Viewed by 3086
Abstract
The scientific knowledge already attained regarding the way severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infects human cells and the clinical manifestations and consequences for Coronavirus Disease 2019 (COVID-19) patients, especially the most severe cases, brought gut microbiota into the discussion. It has [...] Read more.
The scientific knowledge already attained regarding the way severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infects human cells and the clinical manifestations and consequences for Coronavirus Disease 2019 (COVID-19) patients, especially the most severe cases, brought gut microbiota into the discussion. It has been suggested that intestinal microflora composition plays a role in this disease because of the following: (i) its relevance to an efficient immune system response; (ii) the fact that 5–10% of the patients present gastrointestinal symptoms; and (iii) because it is modulated by intestinal angiotensin-converting enzyme 2 (ACE2) (which is the virus receptor). In addition, it is known that the most severely affected patients (those who stay longer in hospital, who require intensive care, and who eventually die) are older people with pre-existing cardiovascular, metabolic, renal, and pulmonary diseases, the same people in which the prevalence of gut microflora dysbiosis is higher. The COVID-19 patients presenting poor outcomes are also those in which the immune system’s hyperresponsiveness and a severe inflammatory condition (collectively referred as “cytokine storm”) are particularly evident, and have been associated with impaired microbiota phenotype. In this article, we present the evidence existing thus far that may suggest an association between intestinal microbiota composition and the susceptibility of some patients to progress to severe stages of the disease. Full article
(This article belongs to the Special Issue The Microbiome/Virome Interface during COVID-19)
Show Figures

Figure 1

Review
Intestinal Barrier Function in Health and Disease—Any Role of SARS-CoV-2?
Microorganisms 2020, 8(11), 1744; https://doi.org/10.3390/microorganisms8111744 - 06 Nov 2020
Cited by 3 | Viewed by 1172
Abstract
Alterations in the structure and function of the intestinal barrier play a role in the pathogenesis of a multitude of diseases. During the recent and ongoing coronavirus disease (COVID-19) pandemic, it has become clear that the gastrointestinal system and the gut barrier may [...] Read more.
Alterations in the structure and function of the intestinal barrier play a role in the pathogenesis of a multitude of diseases. During the recent and ongoing coronavirus disease (COVID-19) pandemic, it has become clear that the gastrointestinal system and the gut barrier may be affected by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus, and disruption of barrier functions or intestinal microbial dysbiosis may have an impact on the progression and severity of this new disease. In this review, we aim to provide an overview of current evidence on the involvement of gut alterations in human disease including COVID-19, with a prospective outlook on supportive therapeutic strategies that may be investigated to rescue intestinal barrier functions and possibly facilitate clinical improvement in these patients. Full article
(This article belongs to the Special Issue The Microbiome/Virome Interface during COVID-19)
Show Figures

Figure 1

Back to TopTop